Why Recurrent BV Keeps Returning and How to Stop It

Bacterial vaginosis comes back after treatment more often than not. Even with a standard week-long course of oral metronidazole, which clears symptoms in roughly four out of five women in the short term, about 58% experience a recurrence within 12 months.¹ That pattern of “treat, improve, relapse” is the defining frustration of recurrent BV, and it traces to causes that antibiotics alone were never designed to fix.

Why Standard Antibiotics Fail to Keep BV Away

The bacteria behind BV do not float around individually in the vaginal canal waiting to be picked off by metronidazole. They form a structured, multi-species biofilm that adheres tightly to the vaginal lining. This biofilm acts as a physical shield: antibiotics can kill some of the free-floating bacteria released from its surface, but the organisms embedded within the structure tolerate drug concentrations that would otherwise destroy them.² Lab experiments have shown that when three common BV-associated species grow together in a biofilm, both metronidazole and clindamycin fail to reduce the biofilm’s overall mass, even though they can lower the number of culturable cells by a modest amount. The interplay between species in the biofilm appears to make at least some of them more tolerant to metronidazole than they would be alone.³

So what happens after you finish a course of antibiotics is predictable: the biofilm remnants seed a fresh population of BV-associated bacteria, symptoms return, and the cycle starts over. Interestingly, research suggests that antibiotic resistance itself is not usually the core problem. Instead, treatment failure is more closely linked to whether healthy lactobacilli can successfully recolonize the vagina once the antibiotics have done their job.⁴ If the lactobacilli don’t bounce back, the conditions remain hospitable for the BV biofilm to regrow.

The Mucus Problem

One reason BV-associated bacteria gain such a foothold involves what they do to the vagina’s protective mucus layer. Gardnerella vaginalis, the species most consistently linked to BV, produces enzymes called sialidases that chew through sugar molecules on the surface of mucus.⁵ By stripping away these sugars, the bacteria degrade the mucus barrier that would otherwise help block them from attaching and colonizing. It’s not just Gardnerella doing this. Prevotella species, another major BV player, also produce sialidases that can break down mucus components, and elevated sialidase activity in the vaginal tract is strongly associated with both BV and adverse outcomes like preterm birth.⁶ This mucus degradation makes it easier for BV organisms to attach, colonize, and spread, while also feeding the bacteria themselves, since the broken-down sugar residues serve as nutrients.⁷

What Triggers Recurrences

Many women who deal with repeated BV describe a “flare-up” pattern rather than a completely new infection each time. In qualitative research, the triggers women most commonly report fall into two broad categories: menstrual-cycle-related and sexual-activity-related.⁸

Menstruation tops the list. Blood has a near-neutral pH, which temporarily raises the pH of the normally acidic vagina, creating conditions that favor anaerobic BV bacteria over protective lactobacilli. On top of that, lactobacilli can physically clump onto red blood cells, effectively lowering their concentration in vaginal fluid during and shortly after a period.⁹ This means the few days around menstruation are a window of vulnerability. Women with heavier or longer periods may face a wider window.

Beyond menstruation, women frequently cite exercise, tight clothing, psychological stress, unprotected intercourse, and oral sex as factors that seem to worsen symptoms.¹⁰ The mechanism behind each varies. Semen, for instance, is alkaline and deposits BV-associated bacteria directly. Stress affects immune function. These are not definitive causes in every case, but they represent the patterns women consistently describe.

The Immune System’s Role

Your body’s immune response in the vaginal tract matters more than people generally assume. BV is more common in women who are immunosuppressed, and several known risk factors for BV are associated with lower concentrations of local immune molecules in vaginal fluid.¹¹ There is an interesting paradox here: while lower immune activity in the vagina seems to make BV more likely, the complications associated with BV, like increased HIV susceptibility and preterm birth, are linked to heightened inflammation. So the immune response in BV is not simply “too weak” or “too strong.” It’s dysregulated.

Research tracking immune markers in vaginal fluid has found that when the vaginal microbiome shifts toward a healthier state, certain protective chemokines increase.¹² This suggests the immune system and the microbiome talk to each other: healthier bacteria promote a more appropriate immune response, and a better immune environment helps healthy bacteria thrive. Breaking this feedback loop in the wrong direction is one reason recurrent BV can feel so self-perpetuating.

Does Treating a Male Partner Help?

This has been one of the most debated questions in BV research, and the answer depends on what “treating the partner” actually involves. A 2025 randomized trial from Australia tested a combined approach: male partners of women with BV received both oral antibiotics and a topical penile antibiotic. Women whose partners got this combined treatment had a recurrence rate of about 35%, compared with 63% in the group where only the woman was treated. That translated to roughly 2.6 fewer recurrences per woman per year.¹³

Those results generated significant excitement. But a subsequent meta-analysis that pooled this trial with earlier studies found no overall benefit from male partner treatment when combining all the data. The pooled result was essentially neutral. When the researchers removed the Australian trial from the analysis (because it was the only study that used both oral and topical treatment for the male partner), the remaining studies showed zero effect and no inconsistency between them.¹⁴ The takeaway is nuanced: giving a male partner a pill alone probably does not help, but the specific combined oral-plus-topical penile regimen from the Australian trial may be uniquely effective. Whether that finding replicates in larger and more diverse populations remains to be seen. An economic evaluation of that trial found it would likely be cost-effective if the results hold up.¹⁵

Suppressive Antibiotic Therapy

For women with frequent recurrences, some clinicians prescribe a longer suppressive course rather than the standard one-and-done treatment. The typical approach involves an initial extended course of oral metronidazole (taken twice daily for 10 to 14 days), followed by twice-weekly vaginal metronidazole gel for three to six months.¹⁶

A randomized trial of this strategy showed clear benefits during the suppressive phase: about 26% of women on vaginal metronidazole gel had a recurrence over 16 weeks, compared with roughly 59% on placebo. But the effect eroded after stopping. By 28 weeks, recurrence had climbed to about 51% in the treated group versus 75% on placebo. The probability of staying BV-free dropped steadily once the suppressive gel was withdrawn.¹⁷ So suppressive therapy buys time and reduces symptom burden, but for many women it postpones the problem rather than solving it permanently.

Boric acid suppositories are sometimes added to suppressive regimens, not as a standalone antibiotic, but as a biofilm disruptor. The idea is that boric acid may help strip away the biofilm coating, exposing the BV organisms to the antibiotic that follows. Clinicians who use this approach typically administer boric acid at the same time as the antibiotic rather than before or after.¹⁸ Evidence for boric acid’s role in this context is still limited to observational reports, not large trials, so it’s an area where clinical practice runs ahead of firm proof.

Live Biotherapeutics and Probiotics

Because failed restoration of lactobacilli is central to BV recurrence, a logical strategy is to deliver the right lactobacilli directly. The most studied product in this space is Lactin-V, a live preparation of Lactobacillus crispatus (strain CTV-05). L. crispatus is the species most associated with a healthy vaginal environment: vaginas dominated by this bacterium tend to have the lowest pH, the lowest levels of inflammatory molecules, and the lowest risk of gynecological complications.¹⁹

In a randomized trial, women who used Lactin-V vaginally after completing metronidazole treatment had a recurrence rate of about 30% by 12 weeks, versus 45% on placebo. By 24 weeks, the benefit held: the risk of recurrence was reduced by roughly a quarter compared to placebo.²⁰ That’s a meaningful improvement, though it still leaves many women experiencing recurrence. A secondary analysis of the same trial uncovered an important detail: the benefit was concentrated in women who had achieved a clear clinical cure from metronidazole before starting Lactin-V. Among those women, the risk of recurrence was nearly halved. Among women who still had BV signs when they started the probiotic, Lactin-V offered no benefit at all.²¹ In practical terms, this means the probiotic works best as a “seeding” step after the infection is genuinely cleared, not as a rescue when antibiotics have already failed.

A follow-up analysis of the trial also found that Lactin-V produced sustained effects on vaginal immunology even after women stopped using it: women in the treatment group had lower levels of a key inflammatory marker and of a biomarker for epithelial barrier disruption, along with a sustained increase in L. crispatus abundance and a sustained decrease in BV-associated Prevotella.²² That’s encouraging because it suggests the transplanted bacteria can set up lasting residence, though the effect is not universal.

Vaginal Microbiome Transplant

For women with truly intractable BV that has not responded to repeated antibiotic courses, a small exploratory study tested an even more direct approach: vaginal microbiome transplant from healthy donors. Five women received the procedure, and four experienced full long-term remission lasting from 5 to 21 months, with their vaginal flora shifting to a Lactobacillus-dominated composition. One patient had only partial improvement. Three of the four successful cases needed more than one transplant before lasting remission took hold, and one required a switch to a different donor.²³ No adverse effects were observed, but the study involved only five patients. Larger randomized trials are needed before this could become a standard treatment. Still, the concept is worth knowing about if you’ve exhausted other options and are looking into what’s on the horizon.

Health Consequences of Repeated BV

Recurrent BV is not just an annoyance. The bacteria involved can ascend from the vagina into the upper reproductive tract, contributing to pelvic inflammatory disease. Research in women at high risk for sexually transmitted infections found that those testing positive for several BV-associated bacteria were at significantly elevated risk of developing PID within three months, and that higher bacterial loads predicted greater risk.²⁴ This type of non-STI-related PID tends to be polymicrobial, driven by BV-associated organisms that migrate upward, and is linked to BV-associated dysbiosis more broadly.²⁵

In pregnancy, the stakes are different. One study of pregnant women at high risk for preterm birth found a significant link between vaginal colonization by a specific Gardnerella species, G. leopoldii, and spontaneous preterm birth.²⁶ A separate trial explored whether oral N-acetyl cysteine could reduce preterm birth in women treated for BV, and found that those receiving it were significantly more likely to reach 36 weeks of pregnancy, with an average gestational age at delivery of about 37 weeks compared to 34 weeks in the placebo group.²⁷ Neither of these findings has been translated into widespread clinical practice yet, but they underline how recurrent BV during pregnancy warrants especially proactive management.

The Emotional Weight of Recurrent BV

Something that rarely gets enough attention is the psychological burden. In survey research, about three-quarters of women with recurrent BV reported a negative impact on their mental health, and a similar proportion said it hurt their sexual health. Roughly two-thirds said it lowered their overall quality of life.²⁸ The biggest toll is often on self-esteem and intimacy. Qualitative research has found that women with recurrent BV regularly avoid sexual activity, particularly oral sex, because of embarrassment and self-consciousness about their symptoms.²⁹

Clinicians sometimes underestimate this dimension because BV is classified as a “mild” infection. But when an infection clears and returns four, five, six times in a year, the cumulative effect on a person’s relationship with their body and their partner is anything but mild. If you’re dealing with this, it’s worth being direct with your healthcare provider about the impact, not just the symptoms. The psychological component is a legitimate reason to pursue more aggressive or experimental treatment strategies rather than accepting repeated standard courses that aren’t working.

Better Diagnostics for Tracking Recurrence

Traditional BV diagnosis relies on clinical indicators: the appearance and smell of discharge, vaginal pH, and a microscopic examination. These methods work for a single point-in-time diagnosis, but they are somewhat subjective and don’t tell you which specific bacteria are present or in what amounts. Molecular diagnostic tools, including quantitative PCR and metagenomic sequencing, are increasingly available and can detect bacteria that are difficult to grow in culture, allow precise measurement of bacterial quantities, and work well with self-collected vaginal swabs.³⁰ For someone with recurrent BV, molecular testing can provide a clearer picture of whether treatment actually eliminated the problem organisms or merely suppressed them temporarily, and it can track whether protective lactobacilli have successfully recolonized. These tests are not yet standard in most primary care settings, but they are becoming more accessible through specialty clinics and some direct-to-consumer services.

Putting a Strategy Together

There is no single fix for recurrent BV, and anyone who tells you otherwise is oversimplifying. But the research points toward a layered approach. First, get a thorough initial clearance with an adequate antibiotic course, potentially longer than the standard seven days. Second, address the biofilm problem if possible, which may mean incorporating boric acid alongside antibiotics. Third, actively try to restore protective lactobacilli, whether through a product like Lactin-V (if available in your region) or other L. crispatus-based options, and do this only after confirming that the antibiotics have actually worked. Fourth, identify and manage your personal triggers, whether that’s adjusting menstrual products, using condoms, or discussing concurrent partner treatment with your doctor. And fifth, for women in sexual relationships with men, pay attention to the evolving evidence on combined oral and topical male partner treatment, particularly if other strategies have failed.

The science around recurrent BV has moved faster in the last five years than in the preceding two decades. Biofilm disruption, live biotherapeutics, vaginal microbiome transplantation, and concurrent partner treatment all represent real, evidence-backed avenues that go beyond the old “here’s another round of metronidazole” approach. The challenge is that much of this is still catching up to clinical practice, and access varies widely. Advocating for yourself with your provider, being specific about how many recurrences you’ve had and what you’ve already tried, is often the most effective step toward getting care that actually matches the complexity of the problem.